Avalo Therapeutics appointed Kevin Lind as a director, effective October 1, 2025, while June Almenoff resigned from the Board on the same date. Lind, previously CEO of Longboard Pharmaceuticals, brings significant experience in healthcare, having raised over $1.1 billion in equity capital; Almenoff's resignation does not relate to company operations.